(S)-4-Carboxyphenylglycine
Tocris Bioscience a Bio-Techne Brand
Key Product Details
Description: | Competitive group I mGlu antagonist; also weak group II agonist |
Alternative Names: | (S)-4CPG |
Purity: | ≥99% (HPLC) |
Molecular Weight: | 195.17 |
Customers also Viewed
Citations for (S)-4-Carboxyphenylglycine (7)
Citations are publications that use Bio-Techne products. Selected citations for (S)-4-Carboxyphenylglycine include:
-
Riz et al.
(2016)
Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming.
Oncotarget.
7:66360
PMID: 27626179 -
Griffin et al.
(2015)
Repeated cycles of chronic intermittent ethanol exposure increases basal glutamate in the nucleus accumbens of mice without affecting glutamate transport.
Front Pharmacol.
6:27
PMID: 25755641 -
Resch et al.
(2014)
Augmented cystine-glutamate exchange by pituitary adenylate cyclase-activating polypeptide signaling via the VPAC1 receptor.
Synapse.
2014;
PMID: 25066643 -
Mahler et al.
(2014)
Modafinil attenuates reinstatement of cocaine seeking: role for cystine-glutamate exchange and metabotropic glutamate receptors.
J Young Investig.
19:49
PMID: 23017017 -
Overocker and Pfau
(2012)
Cytokine Production Modified by System X(c)- After PM10 and Asbestos Exposure.
Proc Natl Acad Sci U S A.
23:34
PMID: 23418405 -
Liu et al.
(2007)
Cystine-glutamate transporter SLC7A11 mediates resistance to geldanamycin but not to 17-(allylamino)-17-demethoxygeldanamycin.
Mol Pharmacol.
72:1637
PMID: 17875604 -
Porter et al.
(2005)
Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity.
J Pharmacol Exp Ther.
315:711
PMID: 16040814
There are no citations that match your criteria.
Customer Reviews for (S)-4-Carboxyphenylglycine (1)
Customer Images
-
Species: HumanAssay Type: In VitroCell Line/Tissue: LP-1 cell lineTreatment with (S)-4-carboxyphenylglycine (CPG) ensitizes LP-1/Cfz cells. Cellswere treated with the indicated concentrations of carfilzomib for 72 hours in the absence or presence of CPG (0.2 uM)
There are no reviews that match your criteria.